Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Steven J. Isakoff, Julia Wulfkuhle et al.|Clinical Cancer Research|2021Cited by 54
Time to treatment and survival in triple negative breast cancer patients receiving trimodality treatment in the United StatesKelsey E. Larson, Debra A. Pratt, SR Grobmyer et al.|Cancer Treatment and Research Communications|2018Cited by 5
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Steven J. Isakoff, Julia Wulfkuhle et al.|Unknown|2023Cited by 1
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Steven J. Isakoff, Julia Wulfkuhle et al.|Unknown|2023Cited by 0
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Steven J. Isakoff, Julia Wulfkuhle et al.|Unknown|2023Cited by 0